Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 178

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 178
---
506

    $
    253,901

    LIABILITIES AND SHAREHOLDERS’ EQUITY

    Current liabilities:

    Accounts payable
     
    $
    3,623

    $
    2,400

    Accrued expenses and other current liabilities

    19,819

    24,057

    Operating lease liabilities, current portion

    1,845

    2,400

    Deferred revenue, current portion

    —

    10,222

    Total current liabilities

    25,287

    39,079

    Operating lease liabilities, net of current portion

    88

    1,010

    Deferred revenue, net of current portion

    —

    1,730

    TOTAL LIABILITIES

    25,375

    41,819

    Commitments and Contingencies

    SHAREHOLDERS’ EQUITY:

    Preferred shares, no par value per share; unlimited shares authorized as of  December 31, 2024 and December 31, 2023; 0 shares issued and outstanding  as of December 31, 2024 and December 31, 2023

    —

    —

    Common shares, no par value per share; unlimited shares authorized as    of  December 31, 2024 and December 31, 2023; 42,510,708 and 42,176,041    shares issued and outstanding as of December 31, 2024 and December 31, 2023,   respectively

    486,674

    483,350

    Warrants

    10

    —

    Additional paid-in capital

    82,191

    61,813

    Accumulated other comprehensive income

    54

    28

    Accumulated deficit

    (417,798
    )

    (333,109
    )

    TOTAL SHAREHOLDERS’ EQUITY

    151,131

    212,082

    TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
     
    $
    176,506

    $
    253,901

The accompanying notes are an integral part of these consolidated financial statements 

102

Repare Therapeutics Inc. 

Consolidated Statements of Operations and Comprehensive Loss 

(In thousands of U.S